tldrdailynews.com logo
Tag

In Vivo Car T

All articles tagged with #in vivo car t

Moderna bets on off-the-shelf in vivo CAR-T for autoimmune disease
technology18 days ago

Moderna bets on off-the-shelf in vivo CAR-T for autoimmune disease

Moderna disclosed its first in vivo CAR-T program, mRNA-6007, which uses a lipid nanoparticle to deliver CAR-T mRNA to CD4/CD8 T and NK cells to target and deplete pathogenic B cells in autoimmune diseases. Marketed as an off-the-shelf approach, it aims to simplify manufacturing and expand access versus traditional ex vivo CAR-T. The therapy is in early IND-enabling stages and is slated to enter the clinic next year, with lupus and other B-cell–mediated conditions among the initial targets; if successful, it could enable larger-scale development, including future oncology applications.

via Fierce Biotech|
#autoimmune-diseases#in-vivo-car-t#lupus
Lilly-backed in vivo CAR-T delivers durable MRD-negativity in multiple myeloma
healthcare1 month ago

Lilly-backed in vivo CAR-T delivers durable MRD-negativity in multiple myeloma

Kelonia Therapeutics’ KLN-1010, an off-the-shelf in vivo CAR-T for BCMA in relapsed/refractory multiple myeloma, produced MRD-negativity in all 18 treated patients at one month, with all assessable patients remaining MRD-negative at six months and the longest follow-up over 10 months. The safety profile is favorable (mostly grade 1–2 CRS and two ICANS cases). Lilly’s $3.2 billion deal for Kelonia could accelerate moving KLN-1010 into earlier lines and set the stage for phase 3 trials and broader in vivo CAR-T applications across cancer types.

via Fierce Biotech|
#healthcare#in-vivo-car-t#kelonia
Lilly’s Kelonia Buyout Tightens the In Vivo CAR-T M&A Frontier
business2 months ago

Lilly’s Kelonia Buyout Tightens the In Vivo CAR-T M&A Frontier

Eli Lilly agreed to pay up to $7 billion for Kelonia Therapeutics, marking another high-profile in vivo CAR-T deal as Big Pharma bets on the space; analysts say deal activity may slow due to a shrinking pool of viable targets, with Umoja Biopharma identified as a prime remaining buyout candidate and offshore players like Starna Therapeutics likely to surface. The pace will hinge on Kelonia’s data and whether the platform can extend beyond oncology into autoimmune indications.

via Fierce Biotech|
#biotech-manda#business#cell-therapy
business2 months ago

Lilly to Acquire Kelonia for Up to $7B to Advance In Vivo CAR-T Therapy

Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion, with $3.25 billion upfront and the rest tied to milestones, in a deal expected to close in the second half of 2026. Kelonia’s in vivo CAR-T technology aims to reprogram patients’ T-cells inside the body to attack cancer, potentially offering a one-time IV therapy compared with traditional ex vivo CAR-T. Lilly plans to apply the tech beyond multiple myeloma to other blood cancers and possibly solid tumors, as part of a broader push to diversify beyond obesity and diabetes drugs amid ongoing biotech dealmaking and competition from J&J and Gilead-backed therapies.

via CNBC|
#business#cancer-immunotherapy#eli-lilly
Lilly bets on in vivo CAR-T with $2.4B Orna Therapeutics deal
biotech5 months ago

Lilly bets on in vivo CAR-T with $2.4B Orna Therapeutics deal

Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to gain an in vivo CAR-T platform using engineered circular RNA delivered by lipid nanoparticles, led by ORN-252 targeting CD19 for autoimmune diseases; terms include upfront and milestone-based payments. The deal follows a wave of pharma acquisitions in this space as Lilly expands its genetic medicines pipeline and Orna has drawn funding and collaborations since its 2021 launch.

via Fierce Biotech|
#biotech#circular-rna#in-vivo-car-t
business5 months ago

Lilly to acquire Orna, betting on in vivo CAR-T and circular RNA medicines

Eli Lilly will acquire Orna Therapeutics in a deal potentially worth up to $2.4 billion to accelerate in vivo CAR-T therapies using circular RNA and lipid nanoparticle delivery, led by ORN-252 targeting CD19 for B cell–driven autoimmune diseases and offering potentially more durable protein expression than current RNA or ex vivo approaches.

via Eli Lilly|
#business#circular-rna#in-vivo-car-t